Johnson A G, Seidemann P, Day R O
Department of Clinical Pharmacology, Princess Alexandra Hospital, Brisbane, Australia.
Int J Clin Pharmacol Ther. 1994 Oct;32(10):509-32.
The prevalence and incidence of adverse drug interactions involving NSAIDs remain unknown. To identify those proposed drug interactions of greatest clinical significance, it is appropriate to focus on interactions between commonly used and/or commonly coprescribed drugs, interactions for which there are numerous well documented case reports in reputable journals, interactions validated by well designed in vivo human studies and interactions affecting high-risk drugs and/or high-risk patients. While most interactions between NSAIDs and other drugs are pharmacokinetic, NSAID-related pharmacodynamic interactions may be considerably more important in the clinical context. However, prescriber ignorance is likely to be a major determinant of many adverse drug interactions. Adverse drug interactions involving NSAIDs may be restricted by rational prescribing and by careful monitoring, particularly high-risk patients, drugs and therapy periods. Prescribing NSAIDs is relatively contra-indicative for patients on oral anticoagulants due to hemorrhage and for patients taking high dose methotrexate due to bone marrow toxicity, renal failure and hepatic dysfunction. Combination NSAID therapy cannot be justified since toxicity may be increased without any improvement in efficacy. Where lithium or antihypertensives are coprescribed with NSAIDs, aspirin or sulindac are preferred and close monitoring is mandatory for lithium toxicity and hypertension respectively. Phenytoin or oral hypoglycemic agents may be administered with NSAIDs other than pyrazoles and salicylates, provided, the patients are monitored carefully at the initiation and cessation of NSAID treatment. Digoxin, aminoglycosides and probenecid may be coprescribed with NSAIDs but close monitoring is required, particularly for high-risk patients such as the elderly. Indomethacin and triamterine should be avoided due to the risk of renal failure, high dose aspirin should be replaced by naproxen in patients on sodium valproate and care is required when corticosteroids are administered to patients taking salicylates long term in high dosage. Interactions between NSAIDs and antacids or cholestyramine are generally avoidable by administering these drugs at different times.
涉及非甾体抗炎药(NSAIDs)的药物不良相互作用的患病率和发病率尚不清楚。为了确定那些具有最大临床意义的药物相互作用,应关注常用和/或常联合使用药物之间的相互作用、在著名期刊上有大量充分记录的病例报告的相互作用、经精心设计的人体体内研究验证的相互作用以及影响高危药物和/或高危患者的相互作用。虽然NSAIDs与其他药物之间的大多数相互作用是药代动力学方面的,但在临床环境中,与NSAIDs相关的药效学相互作用可能更为重要。然而,处方医生的无知可能是许多药物不良相互作用的主要决定因素。涉及NSAIDs的药物不良相互作用可通过合理处方和仔细监测,特别是对高危患者、药物和治疗期的监测来加以限制。由于出血风险,NSAIDs的处方对于口服抗凝剂治疗的患者相对禁忌;由于骨髓毒性、肾衰竭和肝功能障碍,对于服用高剂量甲氨蝶呤的患者也相对禁忌。联合使用NSAIDs治疗不合理,因为这样可能会增加毒性而疗效却没有任何改善。当锂盐或抗高血压药与NSAIDs联合使用时,首选阿司匹林或舒林酸,并且分别必须密切监测锂盐毒性和高血压。除吡唑类和水杨酸盐类外,苯妥英或口服降糖药可与NSAIDs联合使用,但前提是在NSAIDs治疗开始和结束时对患者进行仔细监测。地高辛、氨基糖苷类和丙磺舒可与NSAIDs联合使用,但需要密切监测,特别是对于老年人等高风险患者。由于存在肾衰竭风险,应避免使用吲哚美辛和氨苯蝶啶;在服用丙戊酸钠的患者中,高剂量阿司匹林应替换为萘普生;当长期高剂量服用水杨酸盐的患者使用皮质类固醇时需要谨慎。NSAIDs与抗酸剂或考来烯胺之间的相互作用通常可通过在不同时间服用这些药物来避免。